Every 10-Q that STIMCELL ENERGETICS INC (STME) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow STME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STME filings page.
StimCell Energetics Inc. reported a net loss of $169,518 for the three months ended August 31, 2026, versus $265,602 a year earlier, and no revenue in either period. Operating expenses were $146,558, compared with $252,354. It used $108,995 in operating cash and ended the quarter with $6,883 cash and a $1,971,527 working-capital deficit.
Management said these conditions and dependence on additional financing raise substantial doubt about the company’s ability to continue as a going concern within one year after the interim statements are issued. The company borrowed $112,826 under related-party credit lines to fund operations and plans to seek debt or equity financing; it said financing availability cannot be assured. A $30,000 note owed to CEO and director David Jeffs and a separate $30,000 note owed to director and significant shareholder Amir Vahabzadeh were in default at August 31, 2026.
The eBalance microcurrent-device redesign continued, with $42,558 in quarterly research and development costs. Management concluded disclosure controls and procedures were not effective because of a lack of segregation of duties.
Stimcell Energetics Inc. reported no revenue and a larger loss as it invests in redesigning its eBalance® microcurrent device. For the nine months ended February 28, 2026, the company recorded a net loss of $665,916, nearly double the prior-year period.
Cash was only $10,257, with a working capital deficit of $1,678,420 and an accumulated deficit of $11,527,472. Management discloses “substantial doubt” about the ability to continue as a going concern and is relying heavily on related-party funding.
Operating expenses rose 92.1% year over year to $617,308, driven by $311,290 in general and administrative costs, including $250,000 of non-cash investor relations paid in shares, and $144,905 of research and development tied to the ADM Tronics redesign project.
Stimcell Energetics Inc. reported another quarter with no revenue and a larger loss as it continues to fund early-stage biotech development through related-party debt and stock issuance. For the quarter ended November 30, 2025, the company recorded a net loss of $309,748, bringing the six‑month loss to $575,350, up sharply from the prior year as operating expenses more than doubled. General and administrative costs surged due largely to $250,000 of investor relations services paid in shares, while research and development reached $108,344 as work resumed on redesigning the eBalance® home microcurrent device with ADM Tronics.
The balance sheet remains highly stretched, with total assets of $52,345, cash of just $46,159, and a working capital deficit of $1,542,294. Total liabilities were $1,594,639, including $708,923 in notes and advances due to related parties and $546,447 in other related‑party payables. Management discloses an accumulated deficit of $11,436,906 and explicitly states there is substantial doubt about the company’s ability to continue as a going concern without new financing.
To keep operating, Stimcell borrowed $214,248 during the six months from major shareholders and family members under unsecured credit lines bearing 10% interest, compounded monthly and payable on demand. Despite this fragile position, the company is pushing ahead with product development and a new research collaboration with the St. Boniface Hospital Albrechtsen Research Centre to study the eBalance® device’s effects on mitochondrial function in sensory neurons.
Stimcell Energetics Inc. (STME) reported a wider quarterly loss and tight liquidity in its Q1 FY2026 (three months ended August 31, 2025). Net loss was $265,602 versus $66,919 a year ago as operating expenses rose to $252,354 (from $59,636), driven by higher general and administrative costs and renewed R&D. The company ended the quarter with $6,437 in cash and a working capital deficit of $1,393,949. Total liabilities were $1,410,336 and stockholders’ deficit was $(1,393,949).
Management disclosed substantial doubt about going concern. Operations used $108,142 of cash; financing provided $100,000 from a related-party credit line at 10% per annum. The company issued 375,000 shares for services valued at $120,000 during the quarter and a subsequent 125,000 shares valued at $33,750. R&D was $57,309, tied to the eBalance redesign with ADM Tronics. Internal controls over disclosure were assessed as not effective due to lack of segregation of duties. Common shares outstanding were 20,641,272 as of October 14, 2025.